AbbVie will take the lead on commercializing Regenxbio’s gene therapy in wet AMD and diabetic retinopathy. It’s AbbVie’s second major gene therapy deal this year, coming months after it committed $90 million to preclinical-stage Capsida Biotherapeutics.
Washington, D.C.-based gene therapy outfit Regenxbio just raised $30 million to bring its platform into the clinic. The dollars will help Regenxbio generate clinical proof of concept data, as well as work toward in-licensing new programs. The company’s also using the money to beef up its clinical and manufacturing processes, it said in a statement. Regenxbio has developed […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.